GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-19. Numbers and descriptions here follow the published literature rather than marketing material.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
In the West, the glass is normally a borosilicate glass (similar to Pyrex), while in the former Soviet Union it is normal to use a phosphate glass. The amount of fission products in the glass must be limited because some (palladium, the other Pt group metals, and tellurium) tend to form metallic phases which separate from the glass. Bulk vitrification uses electrodes to melt soil and wastes, which are then buried underground. In Germany, a vitrification plant is treating the waste from a small demonstration reprocessing plant which has since been closed.
== Genetics == The gene for G-CSF is located on chromosome 17, locus q11.2-q12. Nagata et al. found that the GCSF gene has four introns, and that two different polypeptides are synthesized from the same gene by differential splicing of mRNA. The two polypeptides differ by the presence or absence of three amino acids. Expression studies indicate that both have authentic GCSF activity. It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element.
"Assassination on City Hall": dominated by Germans, the Execution Department of Worker's and Soldier's Council proceeded to Poznań's City Hall, an armed group of Poles forces it to change four of the German delegates with Polish ones: Bohdan Hulewicz, Mieczysław Paluch, Henryk Śniegocki and Zygmunt Wiza. Poles thus gain control over the headquarters of Poznań Garrison and 5th Corps. 17 November 1918: the Commission of the NRL calls for a one-time collection of money called a "national tax". 18 November 1918: elections to Poviat's People's Councils and members of the partition's Sejm (1399 MPs). 20 November 1918: the Polish government in Warsaw publishes przyłączenie Wielkopolski będzie jednym z pierwszych naszych zadań (the joining of Greater Poland will be one of our first tasks). 3 December 1918: The Partition Sejm of Poznań begins its official proceedings in the "Apollo" Cinema. MPs represent all lands of the Prussian Partition and Polish economic emigration, mainly from Westfalen. 5 December 1918: the end of the Partition Sejm, which declared its desire for unification with the other partitions in a renewed Poland, and the NRL officially elected its members. 6 December 1918: the first meeting of the NRL has Bolesław Krysiewicz become the speaker. Election of executive body, Commission of the NRL, formed by representatives of Greater Poland - Stanisław Adamski and Władysław Seyda; Upper Silesia: Wojciech Korfanty and Józef Rymer; Eastern Pomerania: Stefan Łaszewski; Kuyavia: Adam Poszwiński.
=== Synthetic alizarin === Natural Alizarin was the first colorant to have its structure determined, making it one of the first targets for synthesis. The first synthesis of alizarin was patented by Carl Graebe and Carl Liebermann in 1868. It entailed the dibromination of anthraquinone, followed by fusion with sodium hydroxide. The second, much cheaper, synthetic path was developed in 1869 by Graebe, Liebermann and Heinrich Caro. It entailed the treatment of anthraquinone with fuming sulphuric acid, followed by a treatment with sodium hydroxide and potassium chlorate. Perkin submitted his own patent for a nearly identical process just a day later, and was awarded the patent in England.
Several months after qualifying as a lecturer in philosophy, Adorno delivered an inaugural lecture at the Institute for Social Research, an independent organization that had recently appointed Horkheimer as its director and, with the arrival of the literary scholar Leo Löwenthal, social psychologist Erich Fromm, and philosopher Herbert Marcuse, sought to exploit recent theoretical and methodological advances in the social sciences. His lecture "The Actuality of Philosophy" created a scandal.
Sources: en.wikipedia.org
=== MeSH D12.644.276 – intercellular signaling peptides and proteins === MeSH D12.644.276.100 – angiogenic proteins MeSH D12.644.276.100.100 – angiopoietins MeSH D12.644.276.100.100.100 – angiopoietin-1 MeSH D12.644.276.100.100.200 – angiopoietin-2 MeSH D12.644.276.100.450 – angiostatic proteins MeSH D12.644.276.100.450.500 – angiostatins MeSH D12.644.276.100.450.750 – endostatins MeSH D12.644.276.100.800 – vascular endothelial growth factors MeSH D12.644.276.100.800.200 – vascular endothelial growth factor a MeSH D12.644.276.100.800.300 – vascular endothelial growth factor b MeSH D12.644.276.100.800.400 – vascular endothelial growth factor c MeSH D12.644.276.100.800.500 – vascular endothelial growth factor d MeSH D12.644.276.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived MeSH D12.644.276.174 – cytokines MeSH D12.644.276.174.050 – autocrine motility factor MeSH D12.644.276.174.200 – chemokines MeSH D12.644.276.174.200.070 – beta-thromboglobulin MeSH D12.644.276.174.200.100 – chemokines, c MeSH D12.644.276.174.200.110 – chemokines, cc MeSH D12.644.276.174.200.120 – chemokines, cxc MeSH D12.644.276.174.200.130 – chemokines, cx3c MeSH D12.644.276.174.200.508 – interleukin-8 MeSH D12.644.276.174.200.600 – macrophage inflammatory proteins MeSH D12.644.276.174.200.600.500 – macrophage inflammatory protein-1 MeSH D12.644.276.174.200.610 – monocyte chemoattractant proteins MeSH D12.644.276.174.200.610.600 – monocyte chemoattractant protein-1 MeSH D12.644.276.174.200.700 – platelet factor 4 MeSH D12.644.276.174.200.750 – rantes MeSH D12.644.276.174.400 – growth substances MeSH D12.644.276.174.400.442 – hematopoietic cell growth factors MeSH D12.644.276.174.400.442.240 – colony-stimulating factors MeSH D12.644.276.174.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.075.350.275 – filgrastim MeSH D12.644.276.174.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.150 – erythropoietin MeSH D12.644.276.174.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.644.276.174.400.442.240.150.250.250 – epoetin alfa MeSH D12.644.276.174.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.644.276.174.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.350.375.275 – filgrastim MeSH D12.644.276.174.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.400 – interleukin-3 MeSH D12.644.276.174.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.750 – thrombopoietin MeSH D12.644.276.174.400.442.800 – stem cell factor MeSH D12.644.276.174.400.505 – interleukins MeSH D12.644.276.174.400.505.501 – interleukin-1 MeSH D12.644.276.174.400.505.502 – interleukin-2 MeSH D12.644.276.174.400.505.503 – interleukin-3 MeSH D12.644.276.174.400.505.504 – interleukin-4 MeSH D12.644.276.174.400.505.505 – interleukin-5 MeSH D12.644.276.174.400.505.506 – interleukin-6 MeSH D12.644.276.174.400.505.507 – interleukin-7 MeSH D12.644.276.174.400.505.508 – interleukin-8 MeSH D12.644.276.174.400.505.509 – interleukin-9 MeSH D12.644.276.174.400.505.510 – interleukin-10 MeSH D12.644.276.174.400.505.511 – interleukin-11 MeSH D12.644.276.174.400.505.512 – interleukin-12 MeSH D12.644.276.174.400.505.513 – interleukin-13 MeSH D12.644.276.174.400.505.514 – interleukin-14 MeSH D12.644.276.174.400.505.515 – interleukin-15 MeSH D12.644.276.174.400.505.516 – interleukin-16 MeSH D12.644.276.174.400.505.517 – interleukin-17 MeSH D12.644.276.174.400.505.518 – interleukin-18 MeSH D12.644.276.174.400.800 – transforming growth factor beta MeSH D12.644.276.174.420 – hepatocyte growth factor MeSH D12.644.276.174.440 – interferons MeSH D12.644.276.174.440.890 – interferon type i MeSH D12.644.276.174.440.890.125 – interferon type i, recombinant MeSH D12.644.276.174.440.890.125.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.125.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.125.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.250 – interferon-alpha MeSH D12.644.276.174.440.890.250.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.250.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.250.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.275 – interferon-beta MeSH D12.644.276.174.440.893 – interferon type ii MeSH D12.644.276.174.440.893.510 – interferon-gamma, recombinant MeSH D12.644.276.174.480 – lymphokines MeSH D12.644.276.174.480.350 – interferon type ii MeSH D12.644.276.174.480.372 – interleukin-2 MeSH D12.644.276.174.480.428 – leukocyte migration-inhibitory factors MeSH D12.644.276.174.480.438 – lymphotoxin MeSH D12.644.276.174.480.615 – macrophage-activating factors MeSH D12.644.276.174.480.615.350 – interferon type ii MeSH D12.644.276.174.480.625 – macrophage migration-inhibitory factors MeSH D12.644.276.174.480.640 – neuroleukin MeSH D12.644.276.174.480.700 – suppressor factors, immunologic MeSH D12.644.276.174.480.750 – transfer factor MeSH D12.644.276.174.500 – monokines MeSH D12.644.276.174.500.400 – interleukin-1 MeSH D12.644.276.174.500.800 – tumor necrosis factor-alpha MeSH D12.644.276.174.750 – tumor necrosis factors MeSH D12.644.276.174.750.500 – lymphotoxin MeSH D12.644.276.174.750.750 – tumor necrosis factor-alpha MeSH D12.644.276.211 – endothelial growth factors MeSH D12.644.276.249 – endothelins MeSH D12.644.276.249.225 – endothelin-1 MeSH D12.644.276.249.235 – endothelin-2 MeSH D12.644.276.249.245 – endothelin-3 MeSH D12.644.276.500 – ephrins MeSH D12.644.276.500.100 – ephrin-A1 MeSH D12.644.276.500.200 – ephrin-A2 MeSH D12.644.276.500.300 – ephrin-A3 MeSH D12.644.276.500.400 – ephrin-A4 MeSH D12.644.276.500.500 – ephrin-A5 MeSH D12.644.276.500.600 – ephrin-b1 MeSH D12.644.276.500.700 – ephrin-b2 MeSH D12.644.276.500.800 – ephrin-b3 MeSH D12.644.276.625 – epidermal growth factor MeSH D12.644.276.750 – fibroblast growth factors MeSH D12.644.276.750.110 – fibroblast growth factor 1 MeSH D12.644.276.750.120 – fibroblast growth factor 2 MeSH D12.644.276.750.130 – fibroblast growth factor 3 MeSH D12.644.276.750.140 – fibroblast growth factor 4 MeSH D12.644.276.750.150 – fibroblast growth factor 5 MeSH D12.644.276.750.160 – fibroblast growth factor 6 MeSH D12.644.276.750.170 – fibroblast growth factor 7 MeSH D12.644.276.750.180 – fibroblast growth factor 8 MeSH D12.644.276.750.190 – fibroblast growth factor 9 MeSH D12.644.276.750.200 – fibroblast growth factor 10 MeSH D12.644.276.812 – i-kappa b kinase MeSH D12.644.276.875 – kinins MeSH D12.644.276.875.169 – bradykinin MeSH D12.644.276.875.169.400 – kallidin MeSH D12.644.276.875.654 – kininogens MeSH D12.644.276.875.654.350 – kininogen, high-molecular-weight MeSH D12.644.276.875.654.400 – kininogen, low-molecular-weight MeSH D12.644.276.875.900 – tachykinins MeSH D12.644.276.875.900.354 – eledoisin MeSH D12.644.276.875.900.475 – kassinin MeSH D12.644.276.875.900.500 – neurokinin a MeSH D12.644.276.875.900.550 – neurokinin b MeSH D12.644.276.875.900.800 – physalaemin MeSH D12.644.276.875.900.866 – substance p MeSH D12.644.276.937 – neuregulins MeSH D12.644.276.937.750 – neuregulin-1 MeSH D12.644.276.952 – parathyroid hormone-related protein MeSH D12.644.276.968 – platelet-derived growth factor MeSH D12.644.276.968.650 – proto-oncogene proteins c-sis MeSH D12.644.276.976 – somatomedins MeSH D12.644.276.976.400 – insulin-like growth factor i MeSH D12.644.276.976.420 – insulin-like growth factor ii MeSH D12.644.276.984 – transforming growth factors MeSH D12.644.276.984.700 – transforming growth factor alpha MeSH D12.644.276.984.720 – transforming growth factor beta MeSH D12.644.276.992 – tumor necrosis factors MeSH D12.644.276.992.500 – lymphotoxin MeSH D12.644.276.992.750 – tumor necrosis factor-alpha MeSH D12.644.276.996 – wnt proteins MeSH D12.644.276.996.500 – wnt1 protein MeSH D12.644.276.996.750 – wnt2 protein
This is especially true in the market for cancer drugs, as a 2011 study found that between 2004 and 2010 orphan drug trials were more likely to be smaller and less randomized than their non-orphan counterparts, but still had a higher FDA approval rate, with 15 orphan cancer drugs being approved, while only 12 non-orphan drugs were approved. This allows manufactures to get cost to the point that it is economically feasible to produce these treatments. The subsidies can total up to $30 million per fiscal year in the United States alone.
==== TRAP-seq ==== TRAP-seq is used to identify mRNAs being actively translated in a specific cell type within a tissue or other assortment of cells. The cell type of interest is engineered to express a ribosomal subunit fused to an epitope tag such as green fluorescent protein. After cell lysis, antibodies targeting the epitope are used to isolate mRNAs that are bound to the ribosomes containing the fusion proteins. This RNA is then converted to cDNA and sequenced. This technique specifically identifies mRNAs that are being translated in the cell type of interest.
...we have learned with interest and humility that Dr. Karl Beyer, a vice-president of Merck, Sharpe and Dohme, Rahway, New Jersey, U.S.A., and current president of the American Pharmacological Society, "coined the word (Pharmacometrics) in the early '50s and has been using it in internal reports ever since" (J. R. Vane, personal communication). Moreover, one of the laboratories in the pharmacological department of his Company is "labeled 'Pharmacometrics'"! We do not know in exactly what sense Dr. Beyer has been using the word, though we find it difficult to think of any other legitimate one than that advanced above. We can only hope that he also thinks so and that its use in the title of this book may help to give it the wider currency that we believe it to deserve and all the "priority" rights to Dr. Beyer.
Due to the stabilization of 7s electronic orbitals and destabilization of 6d ones caused by relativistic effects, Cn2+ is likely to have a [Rn]5f146d87s2 electronic configuration, using the 6d orbitals before the 7s one, unlike its homologues. The fact that the 6d electrons participate more readily in chemical bonding means that once copernicium is ionized, it may behave more like a transition metal than its lighter homologues, especially in the possible +4 oxidation state. In aqueous solutions, copernicium may form the +2 and perhaps +4 oxidation states. The diatomic ion Hg2+2, featuring mercury in the +1 oxidation state, is well-known, but the Cn2+2 ion is predicted to be unstable or even non-existent. Copernicium(II) fluoride, CnF2, should be more unstable than the analogous mercury compound, mercury(II) fluoride (HgF2), and may even decompose spontaneously into its constituent elements. As the most electronegative reactive element, fluorine may be the only element able to oxidize copernicium even further to the +4 and even +6 oxidation states in CnF4 and CnF6; the latter may require matrix-isolation conditions to be detected, as in the disputed detection of HgF4. CnF4 should be more stable than CnF2. In polar solvents, copernicium is predicted to preferentially form the CnF−5 and CnF−3 anions rather than the analogous neutral fluorides (CnF4 and CnF2, respectively), although the analogous bromide or iodide ions may be more stable towards hydrolysis in aqueous solution. The anions CnCl2−4 and CnBr2−4 should also be able to exist in aqueous solution.
Sources: en.wikipedia.org
=== Filming continued === Much of the Mobile footage shot by Malmuth was scrapped, although a few local landmarks remain visible in the finished film, such as the Bankhead Tunnel. Filming resumed on July 5. Baxley indicated that he wanted to add two weeks to the schedule and reshoot most of the Mobile scenes to set the entire film on the Gulf Coast. Bosworth claimed to have been told that his family scenes would be included, only to see that option abandoned after production ran out of money, having burnt $4 million of a projected $8 million budget on the discarded material. Bosworth, Henrisksen and Forsythe rewrote some or much of their lines, often on the day of filming. As a result of this unexpected freedom, Henriksen remembered the movie as a particularly enjoyable experience despite its overall travails. The Sheer Yachts boatyard in Ocean Springs was transformed to recreate the Brotherhood's hangout, and host a few ancillary scenes. Bosworth suffered a knee injury at the location on July 11, but did not miss any days. Bosworth performed a higher-than-average share of his stunts, including driving his bike during select action sequences. Baxley's father Paul served as stunt coordinator on the film.
In 1909, German anatomist Korbinian Brodmann published his original research on brain mapping, defining 52 distinct regions of the cerebral cortex, known as Brodmann areas. Modern research through neuroimaging techniques, still uses the Brodmann cerebral cytoarchitectonic map (referring to the study of cell structure) anatomical definitions from this era in continuing to show that distinct areas of the cortex are activated in the execution of specific tasks. During the 20th century, neuroscience began to be recognized as a distinct academic discipline in its own right, rather than as studies of the nervous system within other disciplines. Eric Kandel and collaborators have cited David Rioch, Francis O. Schmitt, and Stephen Kuffler as having played critical roles in establishing the field. Rioch originated the integration of basic anatomical and physiological research with clinical psychiatry at the Walter Reed Army Institute of Research, starting in the 1950s. During the same period, Schmitt established a neuroscience research program within the Biology Department at the Massachusetts Institute of Technology, bringing together biology, chemistry, physics, and mathematics. The first freestanding neuroscience department (then called Psychobiology) was founded in 1964 at the University of California, Irvine by James L. McGaugh. This was followed by the Department of Neurobiology at Harvard Medical School, which was founded in 1966 by Stephen Kuffler.
== Methodology == Isotopes of a chemical element differ only in the mass number. For example, the isotopes of hydrogen can be written as 1H, 2H and 3H, with the mass number superscripted to the left. When the atomic nucleus of an isotope is unstable, compounds containing this isotope are radioactive. Tritium is an example of a radioactive isotope. The principle behind the use of radioactive tracers is that an atom in a chemical compound is replaced by another atom, of the same chemical element. The substituting atom, however, is a radioactive isotope. This process is often called radioactive labeling. The power of the technique is due to the fact that radioactive decay is much more energetic than chemical reactions. Therefore, the radioactive isotope can be present in low concentration and its presence detected by sensitive radiation detectors such as Geiger counters and scintillation counters. George de Hevesy won the 1943 Nobel Prize for Chemistry "for his work on the use of isotopes as tracers in the study of chemical processes". There are two main ways in which radioactive tracers are used
== Determining the RTD experimentally == Residence time distributions are measured by introducing a non-reactive tracer into the system at the inlet. Its input concentration is changed according to a known function and the output concentration measured. The tracer should not modify the physical characteristics of the fluid (equal density, equal viscosity) or the hydrodynamic conditions and it should be easily detectable. In general, the change in tracer concentration will either be a pulse or a step. Other functions are possible, but they require more calculations to deconvolute the RTD curve.
1973); British-Israeli politician, media expert, journalist, media-spokesperson, policy maker; Deputy Mayor of Jerusalem in charge of foreign relations, international economic development and tourism; co-founder of UAE–Israel Business Council; appointed by Israel's foreign minister Eli Cohen as special envoy for innovation; has written editorials, commentary, and op-ed columns for The Telegraph, Jerusalem Post, La Voz de Galicia, Times of Israel, Haaretz, Ynet News, Gulf Business, Arutz Sheva/Israel National News, Algemeiner Journal, Jewish Journal (Los Angeles), Jewish News, JNS, Jüdische Allgemeine, Salem Radio Network News, The Media Line, The Detroit Jewish News, Jewish Policy Center, Israel Behind The News, The Jewish World, Jewish Chronicle; previously served as president of King's College Jewish Society; was barrister at Middle Temple; served as campaign director at World Jewish Relief; served as senior associate with American Jewish Joint Distribution Committee; CEO of international strategic communications firm, Message Experts; worked with U.S. State Department on embassy in Jerusalem; one of founders of UAE–Israel Business Council. Dan Neidle (b.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.